Drug giant calls for clarity on Brexit and a minimum two-year transition period to avoid disruption to medical supplies.
Britain’s biggest drugmaker is preparing to build new drug testing facilities in Europe as part of detailed plans in in the event of a failure to agree a Brexit deal.
GlaxoSmithKline chief executive, Emma Walmsley, said drug companies needed clarity on future relations with the EU as soon as possible to minimise disruption to medicine supplies. Walmsley also repeated her earlier call for a transition period of at least two years.
“The most important thing is to get to clarity on an implementation phase for at least two years, potentially longer, but to get clarity on that as soon as possible,” she said.
